The prototypic proinflammatory cytokine IL-1 plays a central role in innate immunity and inflammatory disorders. The formation of mature IL-1 from an inactive pro-IL-1 precursor is produced via nonconventional multiprotein complexes called the inflammasomes, of which the most common is the nucleotide-binding domain leucine-rich repeat-containing protein 3 (NLRP3) inflammasome composed by NLRP3, (ASC) apoptosis-associated speck-like protein containing a caspase activation and recruitment domain (CARD), and caspase-1. Specialized proresolving mediators (SPMs) promote resolution of inflammation, which is an essential process to maintain host health. SPMs prevent excessive inflammation by terminating the inflammatory response and returning to tissue homeostasis without immunosupression. This study tested the hypothesis that modulation of the NLRP3 inflammasome in macrophages is one mechanism involved in the SPM-regulated processes during resolution. Our findings demonstrate that the SPM resolvin D2 (RvD2) suppressed the expression of pro-IL-1 and reduced the secretion of mature IL-1 in bone marrow-derived macrophages challenged with LPS+ATP (classical NLRP3 inflammasome model)
the apoptosis-associated Speck-like protein with a caspase recruitment domain (ASC) to recruit the inactive zymogen procaspase-1. 4 Oligomerization of pro-caspase-1 proteins induces their autoproteolytic cleavage into active caspase-1, a cysteine-dependent protease that cleaves pro-IL-1 and pro-IL-18 to generate the biologically active proinflammatory cytokines IL-1 and IL-18, respectively. [2] [3] [4] Specialized proresolving mediators (SPMs) are potent, local acting lipid mediators endogenously produced from polyunsaturated fatty acid precursors during the inflammation resolution process via a complex coordinated program. 5 SPMs are essential to maintain host homeostasis by actively promoting the timely resolution of inflammation exerting their actions at the nanomolar level. 5 These bioactive lipid mediators prevent excessive inflammation and the return to tissue homeostasis by limiting leukocyte trafficking and the production of chemical proinflammatory mediators such as cytokines, among others. 5 The SPM family is composed of different class members, namely resolvins of the E-series, which are generated from eicosapentaenoic acid, resolvins of the D series generated from docosahexaenoic acid (DHA) and protectins and maresins also derived from DHA. 5 Among the SPM family, in the current study, we focused our attention on resolvins of the D-series and in particular in resolvin (Rv) D1 and RvD2, which are the most widely characterized and their receptors have been identified and cloned. 6, 7 In addition, these SPMs potently reduce the secretion of proinflammatory cytokines by activated macrophages, and more specifically are capable of reducing the expression of IL-1 at the mRNA level in THP-1 monocytic cells, 8 burn wound neutrophils 9 , and vascular smooth muscle cells 10 as well as to reduce the levels of mature IL-1 protein in adipose tissue, 11 liver, 12 and THP-1 macrophages. 13 However, the molecular determinants underlying the modulatory actions of these SPMs on IL-1 levels have not yet been characterized. The aim of the current study was to investigate whether RvD1 and RvD2 were able to modulate the NLRP3 inflammasome in macrophages, thus providing a mechanism by which these SPMs reduce IL-1 formation during the resolution of inflammation. 
MATERIALS AND METHODS

Materials
Animals and in vivo peritonitis model
Male C57BL/6J mice from Charles River Laboratories (Saint Aubin les Elseuf, France) were housed in wood-chip bedding cages with 50-60%
humidity and a 12-h light/dark cycle and given free access to food and water. Murine peritonitis was induced by intraperitoneal (i.p.)
administration of zymosan A at 1 mg/mouse, suspended in 1 mL of sterile saline with or without RvD1 or RvD2 (300 ng/mouse). This dose was chosen based on our own preliminary data and other studies from the literature. 12, 14 At selected time intervals (4, 12, and 24 h), mice were euthanized with isofluorane overdose and peritoneal exudates were collected by lavaging the peritoneum with 7 mL of ice-cold DPBS − . To isolate intraperitoneal macrophages, the exudates were centrifuged at 500 g for 5 min and the pellet resuspended in DMEM supplemented with penicillin (100 U/mL), streptomycin (100 mg/mL), L-glutamine (2 mM), and 5% FBS. Cells (1.4 × 10 6 or 7 × 10 5 cells/well seeded on 6-or 12-well culture plates, respectively) were allowed to adhere over 2 h at 37 • C in a humidified 5% CO 2 incubator. Nonadherent cells were removed by washing twice with DPBS − , and RNA and protein were extracted from the remaining adherent cells.
In some experiments, macrophages were left growing in DMEM for 12 h and their ability to produce IL-1 was assessed by ELISA.
In another set of experiments, peritoneal exudates were directly processed and labeled for flow cytometry analysis (see below). All animal studies were conducted in accordance with the Investigation and Ethics Committee criteria of the Hospital Clínic and European Union legislation.
Isolation of thioglycolate-recruited peritoneal macrophages
Both resting and thioglycolate-recruited (3 days after i.p. injection of 2.5 mL 3% thioglycolate) peritoneal macrophages from C57BL/6J mice were collected by peritoneal lavage with 7 mL of ice-cold DPBS − . The exudates were treated as above. To assess inflammasome activation, resting cells were exposed to vehicle (0.01% ethanol) and LPS (100 ng/mL) for 4 h and then incubated with ATP (1 h) or sodium palmitate (PA) (200 M) (12 h) with or without RvD1 or RvD2
(10 nM). The concentration of RvD1 and RvD2 was selected from the literature, which indicates that SPMs exert biological actions within the nanomolar range at concentrations as low as 1-10 nM. 5, 15 At the end of the incubation period, medium was collected and macrophages were washed twice with DPBS ++ and then suspended in TRIzol reagent or RIPA buffer (50 mM Tris-HCl, 1 mM EDTA, 1 mM PMSF, 1% Igepal, 0.25% sodium deoxycholate, 1 mM sodium fluoride, 1 mM sodium orthovanadate, 150 mM NaCl, pH 8, with a protease and phosphatase inhibitor mix) for RNA and protein extraction and analysis, respectively.
Isolation of bone marrow-derived macrophages
Mice were anesthetized with isofluorane and sacrificed by cervical dislocation. Bone marrow cells from femurs and tibiae of donor C57BL/6J mice were collected in DPBS − . After centrifugation at 500 g, the cells
were plated at 1 × 10 5 cells/cm 2 in complete DMEM with 30% L929-conditioned medium for macrophage differentiation to bone marrowderived macrophages (BMDM). 16 To study inflammasome activation, the cells were treated as above and RNA and protein were collected. com/pebiodocs/04303859.pdf).
Caspase-1 activity assay
Caspase-1 activity was measured using the Caspase-GLO 
ASC speck formation
Cell viability assay
Thioglycolate-recruited peritoneal macrophages were seeded in 96-well plates (120,000 cells/well) and incubated with vehicle (EtOH), RvD1 (1, 10 and 100 nM) or RvD2 (1, 10 and 100 nM) and MTT
at 37 • C. The reaction was stopped with isopropyl alcohol and shaking for 20 min, and the absorbance at 570 nm of the insoluble formazan was measured in a multiwell plate reader (BMG Labtech, Offenburg, Germany) and cell number was calculated from a standard curve.
IL-1 ELISA assay
Cell supernatants were collected and IL-1 levels were evaluated by ELISA using High Absorbance 96-well plates and mouse IL-1 ELISA and 3,3 ′ ,5,5 ′ -tetramethylbenzidine (TMB) substrate sets from Beckton Dickinson (San Diego, CA), following the manufacturer's instructions.
Western blot analysis
Protein samples in RIPA buffer were quantified with the Micro BCA protein assay kit and subjected to electrophoresis in reducing conditions with 13% (for IL-1 ) or 15% (for caspase-1) poly-acrylamide gels using the Bio-Rad Mini-Protean system. The proteins were transferred to PVDF membranes using the iBlot Dry Blotting system Unstained, single stains, and fluorescence minus one controls were used for setting compensation and gates.
Flow cytometry
Statistical analysis
Statistical analysis of the results was performed by analysis of variance (one-way or two-way ANOVA) or unpaired Student's t-test. The results are expressed as mean ± SEM and differences were considered significant at P < 0.05.
RESULTS
SPMs attenuate LPS-ATP inflammasome activation in BMDM
To investigate whether RvD1 and RvD2 can modulate the NLRP3 inflammasome in macrophages, we exposed BMDM to the classical antagonist of GPR18, the recently described RvD2 receptor 7 (Fig. 1E ).
Protein levels of pro-caspase-1 were not significantly modified by this SPM (Figs. 1A and 1B) . Furthermore, both RvD1 and RvD2 potently inhibited the expression of IL-1 at the mRNA level (Fig. 1F) , indicating that these SPMs primarily block the priming of the NLRP3 inflammasome. Consistent with this view, the mRNA expression of IL-18, another inflammatory cytokine which maturation is also processed by the NLRP3 inflammasome, was also downregulated by RvD1 and RvD2 (Fig. 1G) . The inhibitory actions of these SPMs on inflammasome priming were associated with downregulation of proinflammatory genes such OPN, confirming that the macrophage inflammatory phenotype was toned down by these lipid mediators ( Supplementary   Fig. 1A ). These effects were not associated with changes in cell viability after treatment with RvD1 or RvD2 at the concentrations used in our in vitro studies ( Supplementary Fig. 1B ).
SPMs attenuate LPS-palmitate inflammasome activation in BMDM
To ascertain whether the SPM inhibitory properties were also seen in other models of NLRP3 inflammasome activation, we next challenged BMDM with LPS and palmitate. In these experiments, both No changes in 5-LOX were detected (I).
SPMs attenuate LPS-palmitate inflammasome activation in peritoneal macrophages
To further confirm the modulatory properties of SPMs on the macrophage NLRP3 inflammasome, we next explored the actions of RvD1 and RvD2 on thioglycolate-recruited peritoneal macrophages.
As shown in Fig. 3A (left panel), exposure of peritoneal macrophages to increasing concentrations of LPS (from 0 to 1000 ng/mL) induced the accumulation of the IL-1 precursor pro-IL-1 , while the protein levels of pro-caspase-1 remained unaffected. This induction was also seen in naive Raw 264.7 cells, a murine macrophage cell line (Fig. 3A, right panel) . As expected, the addition of palmitate to LPSstimulated peritoneal macrophages resulted in the activation of the inflammasome manifested in a significant reduction of the levels of unprocessed pro-IL-1 protein (Fig. 3B) , accompanied by an increase in the secretion of mature IL-1 to the media (Fig. 3C) . Incubation of palmitate-challenged peritoneal macrophages with RvD1 or RvD2 was associated with a significant inhibition in pro-IL-1 protein levels without changes in pro-caspase-1 (Fig. 3D ). Similar to that previously seen in BMDM, both RvD1 and RvD2 produced a striking reduction in IL-1 mRNA expression in LPS-palmitate-challenged macrophages Results are expressed as mean + SEM and are pooled from n = 3 experiments that were run in duplicate. *, P < 0.05 versus V; # , P < 0.05 versus LPS-ATP (Fig. 3E) , effects that culminated into a lower secretion of mature IL-1 protein into the media (Fig. 3F) . Caspase-1 mRNA levels in peritoneal macrophages were not greatly affected by SPMs (Fig. 3G) . Of interest, RvD1 and RvD2 did not show additive actions on the LPS priming of IL-1 expression, suggesting different signalling pathways for their actions ( Supplementary Fig. 1D ).
RvD2 inhibits caspase-1 activity in LPS-palmitate-elicited peritoneal macrophages
Once established that variations in IL-1 in response to SPMs occur in the context of reduced inflammasome priming, we next sought to investigate whether these lipid mediators could also modify caspase-1 after RvD2 treatment (Fig. 4D) , confirming that RvD2 did not induce pyroptosis in peritoneal macrophages. This finding was consistent with the observation that RvD2 did not reduce macrophage viability ( Supplementary Fig. 1B ).
RvD2 deactivates NLRP3 inflammasome in zymosan A-induced peritonitis
To translate in vivo the findings obtained in vitro, we next explored the actions of SPMs in an experimental model of murine peritonitis, which is characterized by spontaneous resolution of inflammation within 24 h after the injection of zymosan A. Preliminary observations indicated that RvD2 was the most active SPM of the resolvin D-series in this model, and therefore this lipid mediator was again selected for in vivo studies. Over the course of resolution, the NRLP3 inflammasome was progressively deactivated in peritoneal macrophages resulting in reduced NLRP3 mRNA levels without changes in ASC and caspase-1 (Fig. 5A ). Decreased IL-1 mRNA expression, sustainably lower IL-1 secretion and reduced mature IL-1 levels in the peritoneal exudates were also detected over the resolution process (Fig. 5B) . Although no significant differences were observed in the expression of caspase-1, NLRP3, and ASC, as compared to peritoneal macrophages from mice receiving zymosan A alone (Fig. 5C ), macrophages isolated from (Fig. 5F ).
RvD2 suppresses the inflammatory phenotype while promoting the M2 proresolutive phenotype in peritoneal macrophages
Finally, to prove that inflammasome deactivation by RvD2 in vivo has broader suppressive effects on inflammation than just reducing IL-1 levels, we assessed the cytokine profile in the self-resolving model of zymosan A-induced peritonitis. As shown in Fig. 6A , the process of resolution was associated with downregulation of inflammatory cytokines including IL-6 and TNF-in parallel with an induction of proresolutive M2 markers such as arginase-1 (Arg1) and mannose receptor CD206. Confirmation of the acquisition of a resolution phenotype was obtained by flow cytometry analysis, which revealed a peak in the number of M2 proresolutive (F4/80 + /CD206 + ) macrophages at 24 h after zymosan A injection (Fig. 6B) . Notably, as compared to mice receiving zymosan A alone, macrophages from mice receiving zymosan A and RvD2 exhibited a significantly higher population of proresolutive (F4/80 + /CD206 + ) macrophages at 12 h after zymosan challenge (Fig. 6B) . Consistent with this, at 12 h, RvD2 significantly upregulated Arg1, which is a functional marker of M2 macrophages (Fig. 6C) . Moreover, at this time period, macrophages from mice receiving zymosan A and RvD2 exhibited an attenuated expression of M1 cytokines such as OPN and TNF- (Fig. 6D) . Comparison of the different macrophage populations did not identify any difference in cell viability from RvD2-treated versus nontreated animals ( Supplementary Fig. 1F and Supplementary Fig. 2 ). Together, these data confirm the dominance of proresolving and anti-inflammatory conditions in macrophages from mice receiving the RvD2 treatment.
DISCUSSION
The results of the current study indicate that SPMs are able to modulate IL-1 production in macrophages by inhibiting the priming and repressing the activation of the NLRP3 inflammasome. To reach phagocytes. 24 However, some of the findings of the current study are not in agreement with those previously reported by Yan et al. 25 These investigators tested the effects of omega-3 fatty acids on the NLRP3 inflammasome in PMA-differentiated THP-1 macrophages and BMDM and concluded that the ability of these fatty acids to repress the inflammasome is independent of the transformation of omega-3 precursors into bioactive lipid mediators. 25 Specifically, these authors provided evidence that neither RvD1 nor aspirin-triggered RvD1 and protectin D1 had any effect on nigericin-induced caspase-1 activation and IL-1 secretion by LPS-primed BMDM. 25 Several reasons may account for this discrepancy with our findings. First, Yan et al. used micromolar concentrations of SPMs, hundred-times higher than those employed in our experiments. The actions of lipid mediators are bell shaped, 26 and the use of such high amounts has a likely negative impact on their biological properties. Second, RvD2, which in our study was the most active lipid mediator in inhibiting the priming of inflammasome was not tested by Yan et al. On the other hand, our findings with RvD1 are quite coincidental with theirs because the response to this lipid mediator was also quite modest in our system. Finally, protectin D1 was obtained from commercial sources, and it is widely known that only the protectin D1 isomer called protectin DX, which has no comparable properties, is commercially available. 27 In summary, the present study provides evidence for the ability 
